作者
Mikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, Mirta Diez, Mark C Petrie, Subodh Verma, Jose C Nicolau, Béla Merkely, Masafumi Kitakaze, David L DeMets, Silvio E Inzucchi, Lars Køber, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Scott D Solomon, Olof Bengtsson, Daniel Lindholm, Anna Niklasson, Mikaela Sjöstrand, Anna Maria Langkilde, John JV McMurray
发表日期
2020/1/14
期刊
Circulation
卷号
141
期号
2
页码范围
90-99
出版商
Lippincott Williams & Wilkins
简介
Background
Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status (symptoms, physical function, and quality of life). In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), sodium–glucose cotransporter-2 inhibitor, dapagliflozin, reduced death and hospitalizations, and improved symptoms in patients with heart failure and reduced ejection fraction. In this analysis, we examine the effects of dapagliflozin on a broad range of health status outcomes, using the Kansas City Cardiomyopathy Questionnaire (KCCQ).
Methods
KCCQ was evaluated at randomization, 4 and 8 months. Patients were divided by baseline KCCQ total symptom score (TSS); Cox proportional hazards models examined the effects of dapagliflozin on clinical events across these subgroups. We also evaluated the …
学术搜索中的文章
MN Kosiborod, PS Jhund, KF Docherty, M Diez… - Circulation, 2020